Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 11, 2010, Pages 647-653

  Said, Shehta Abd Allah ^a   El Agamy, Dina Saad ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Curcumin; Hepatotoxicity; Losartan; N Acetylcysteine; Resveratrol; Rosiglitazone; Valproate

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CURCUMIN; LOSARTAN; PENTETRAZOLE; RESVERATROL; ROSIGLITAZONE; TRIACYLGLYCEROL; VALPROIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; LIVER HISTOLOGY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; RAT; SEIZURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78649902448     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296342     Document Type: Article

References (51)

1. Wong H, Rurak DW, Kumar S, Kwan E, Abbott FS, Wayne Riggs K. Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. Drug Metab Dispos. 2001;29(5):664-75.
2. Löscher W. Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669-94.
3. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities III US experience since 1986. Neurology. 1996;46(2):465-9.
4. Jeavons PM. Non-dose-related side effects of valproate. Epilepsia. 1984;25:S50-6.
5. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37(3):379-85.
6. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci. 2005;86(2):427-35.
7. Kassahun K, Abbott F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid. Drug Metab Dispos. 1993;21(6):1098-106.
8. Raza M, Al-Bekairi AM, Ageel AM, Qureshi S. Biochemical basis of sodiumvalproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol Res. 1997;35(2):153-7.
9. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci. 2005;86(2):436-43.
10. Löscher W, Wahnschaffe U, Honack D, Wiltfoht W, Nau H. Effect of valproate and E-2-en-valproate on functional and morphological parameters of rat liver;I. Biochemical histopathological and pharmacokinetic studies. Epilepsy Res. 1992;13(3):187-98.
11. Shapiro H, Ashkenazi M, Weizman N, Shahmurov M, Aeed H, Bruck R. Curcumin ameliorates acute thioacetamide- induced hepatotoxicity. J Gastroenterol Hepatol. 2006;21(2):358-66.
12. Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis. 2006;27(5):1038-46.
13. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati- Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122(7):1924-40.
14. 4. World J Gastroenterol. 2000;6(4): 540-5.
15. Cetinkaya A, Bulbuloglu E, Kurutas EB, Kantarceken B. N-acetylcysteine ameliorates methotrexate-induced oxidative liver damage in rats. Med Sci Monit. 2006;12(8):274-8.
16. 3 receptor antagonist protects against PTZ-induced seizures in mice. Life Sci. 2000;66(22):297-301.
17. DeVane CL. Pharmacokinetics, drug interactions and tolerability of valproate. Psychopharmacol Bull. 2003;37:S25-42.
18. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003;139(2):209-18.
19. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR-γ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43(3):661-6.
20. Uma Devi P, Pillai KK, Vohora D. Modulation of pentylene-tetrazole- induced seizures and oxidative stress parameters by sodium valproate in the absence and presence of N-acetylcysteine. Fundam Clin Pharmacol. 2006;20(3):247-53.
21. Kassahun K, Hu P, Grillo MP, Davis MR, Jin L, Baillie TA. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem Biol Interact. 1994;90(3):253-75.
22. Farrell K, Abbott FS. Role of N-acetylcysteine in the treatment of valproate hepatotoxicity. In: Levy RH, Penry JK, editors. Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity. New York: Raven Press; 1991. p. 149-153.
23. Tong V, Chang TK, Chen J, Abbot FS. The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats. Free Radic Biol Med. 2003;34(11):1435-46.
24. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. AmJ Physiol. 2003;284(2):G321-7.
25. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr. 2001;131(11):2932-2935.
26. Leclercq IA, Farrell GC, Sempoux C, dela-Pena A, Horsmans YJ. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004;41(6):926-34.
27. Kamalakkannan N, Rukkumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative effects of curcumin and an analogue of curcumin in carbon tetrachloride- induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol. 2005;97(1):15-21. (Pubitemid 40896816)
28. Wei QY, Chen WF, Zhou B, Yang L, Liu ZL. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta. 2006;1760(1):70-7.
29. Zheng S, Yumei F, Chen, A. de novo synthesis of glutathione is a prerequisite for curcumin to inhibit HSC activation. Free Radic Biol Med. 2007;43(3):444-53.
30. Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-κB, proinflammatory cytokines production and oxidative stress. Biochim Biophy Acta. 2007;1770(6):989-96.
31. Nishinaka T, Ichijo Y, Ito M, Kimura M, Katsuyama M, Iwata K, et al. Curcumin activates human glutathione-Stransferase P1 expression through antioxidant response element. Toxicol Lett. 2007;170(3):238-47.
32. Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther. 2005;22(10):897-905.
33. Elte JW, Blicklé JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med. 2007;18(1):18-25.
34. Henriksen JH, Ring-Larsen H. Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). J Hepatol. 2008;48(1):174-6.
35. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38(4):1008-17.
36. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003;38(4):434-40.
37. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, et al. Up-regulation of peroxisome proliferator- activated receptors (PPAR-alpha) and PPARgamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma- responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 2000;141(11):4021-31.
38. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2004;315(1):187-95.
39. Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H. The peroxisome proliferator-activated receptor- g agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol Res. 2005;32(4):235-42.
40. Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B. 2006; 7(8):627-33.
41. Leclercq IA, Lebrun VA, Stärkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPAR-γ agonist pioglitazone. Lab Invest. 2007;87(1):56-65.
42. Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E, et al. Rosiglitazone attenuates liver inflammation in a rat model of non-alcoholic steatohepatitis. Dig Dis Sci. 2007; 52(12):3465-72.
43. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004; 351(11):1106-18.
44. Fryer LG, Parbu-Patel A, Carling D. The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002;277(28):25226-32.
45. Donnelly LE, Newton R, Kennedy G E, Fenwick PS, Leung RH, Ito K, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol. 2004;287(4):L774-83.
46. Wolter F, Ulrich S, Stein J. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogues in colorectal cancer: key role of polyamines? J Nutr. 2004; 134(12):3219-22.
47. Cai YJ, Fang JG, Ma LP, Yang L, Liu ZL. Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim Biophys Acta. 2003; 1637(1):31-8.
48. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40(5):1222-5.
49. Aruoma OI, Halliwell B, Hoey BM, Bulter J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-7.
50. Cotgreave IA. N-Acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol. 1997;38:205-27.
51. Federico A, Trappoliere M, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis. 2006;38(11):789-801.